Core - Biomarker Development Laboratory (BDL)

核心 - 生物标志物开发实验室 (BDL)

基本信息

批准号：
10705802
负责人：
JAMES G. HERMAN
金额：
$ 38.24万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-16 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10705802
关键词：
Anatomy Apoptotic Benign Biological Biological Markers Blood Body Fluids Breast Cancer Detection Cancer Etiology Categories Classification Clinical Collection Colorectal DNA DNA Methylation Data Detection Development Diagnosis Diagnostic Diagnostic Procedure Diameter Early Detection Research Network Early Diagnosis Epigenetic Process Event Funding Genetic Head and neck structure Healthcare High Prevalence Histology Laboratories Location Low Prevalence Lung Lung nodule Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Measures Methods Methylation Molecular Monitor Necrosis Nodule Nucleic Acids Pancreas Participant Patients Performance Plasma Process Prostate Reporting Research Design Research Personnel Sampling Screening for cancer Sensitivity and Specificity Source Specimen Standardization Testing The Cancer Genome Atlas Tissues United States Validation biomarker development bisulfite cancer biomarkers cancer type circulating DNA clinical implementation computed tomography screening cost effective design detection assay detection method digital improved laboratory development low dose computed tomography lung cancer screening methylation biomarker mortality multidisciplinary neoplastic cell novel performance tests prospective screening tumor tumor DNA tumorigenesis wasting

项目摘要

As part of a Biomarker Characterization Center, the Biomarker Development Laboratory will develop improved methods to detect DNA methylation changes for the early detection of lung cancer. Led by Dr. James Herman and Dr. Tza-Huei Jeff Wang, a multidisciplinary team of investigators will develop improved panels of DNA methylation alterations able to detect circulating tumor DNA (ctDNA) changes in plasma, to determine the origin of ctDNA from lung cancer or other common malignancies, and to continue improvements in methylation detection methods to better detect the small amounts of ctDNA present in plasma. This EDRN Biomarker Development Laboratory will use high quality, prospectively collected biospecimens to develop highly sensitive, specific and quantitative approaches for the detection of tumor-specific DNA methylation abnormalities in plasma. These methods will be transferred to the Biomarker Reference Laboratory to be standardized and tested for performance in a CLIA setting.

作为生物标志物特征中心的一部分，生物标志物开发实验室将开发改进的方法来检测DNA甲基化变化以早期检测肺癌。由詹姆斯·赫尔曼（James Herman）博士和Tza-huei Jeff Wang博士领导，研究人员团队将开发改进的DNA甲基化改变面板检测血浆中循环肿瘤DNA（CTDNA）的变化，以确定来自肺癌或其他常见恶性肿瘤的CTDNA，并继续改善在甲基化检测方法中，以更好地检测出存在的少量ctDNA 等离子体。这个EDRN生物标志物开发实验室将使用高质量前瞻性收集的生物测量，以发展高度敏感，特异性和检测肿瘤特异性DNA甲基化的定量方法血浆异常。这些方法将转移到生物标志物参考实验室将在CLIA环境中进行标准化和测试。